TWI601532B - 鼻內苯二氮平醫藥組成物 - Google Patents

鼻內苯二氮平醫藥組成物 Download PDF

Info

Publication number
TWI601532B
TWI601532B TW101111309A TW101111309A TWI601532B TW I601532 B TWI601532 B TW I601532B TW 101111309 A TW101111309 A TW 101111309A TW 101111309 A TW101111309 A TW 101111309A TW I601532 B TWI601532 B TW I601532B
Authority
TW
Taiwan
Prior art keywords
weight
administration
individual
pharmaceutical composition
dzns
Prior art date
Application number
TW101111309A
Other languages
English (en)
Chinese (zh)
Other versions
TW201302204A (zh
Inventor
蓋瑞 布里姆
摩利斯Ａ 柯亞拉拉
白洺基
趙載勳
張惠真
Original Assignee
尼羅尼柯公司
愛思開生物製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 尼羅尼柯公司, 愛思開生物製藥股份有限公司 filed Critical 尼羅尼柯公司
Publication of TW201302204A publication Critical patent/TW201302204A/zh
Application granted granted Critical
Publication of TWI601532B publication Critical patent/TWI601532B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW101111309A 2011-03-31 2012-03-30 鼻內苯二氮平醫藥組成物 TWI601532B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161469940P 2011-03-31 2011-03-31

Publications (2)

Publication Number Publication Date
TW201302204A TW201302204A (zh) 2013-01-16
TWI601532B true TWI601532B (zh) 2017-10-11

Family

ID=46928023

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101111309A TWI601532B (zh) 2011-03-31 2012-03-30 鼻內苯二氮平醫藥組成物

Country Status (15)

Country Link
US (3) US20120252793A1 (https=)
EP (1) EP2691100A4 (https=)
JP (1) JP2014509655A (https=)
KR (1) KR20140029426A (https=)
CN (1) CN103619338B (https=)
AR (1) AR085927A1 (https=)
AU (1) AU2012236334B2 (https=)
BR (1) BR112013024968A2 (https=)
CA (1) CA2831308A1 (https=)
MX (1) MX357800B (https=)
PH (2) PH12013501915A1 (https=)
RU (2) RU2013148120A (https=)
SG (2) SG193958A1 (https=)
TW (1) TWI601532B (https=)
WO (1) WO2012135619A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP5929800B2 (ja) * 2012-04-03 2016-06-08 コニカミノルタ株式会社 定着液および画像形成方法
US11020403B2 (en) * 2017-06-02 2021-06-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
US11278492B2 (en) 2018-01-05 2022-03-22 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
JP7492918B2 (ja) 2018-06-04 2024-05-30 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト皮膚浸透ラグタイムを改善する方法及び配合物
CN111529489A (zh) * 2020-04-17 2020-08-14 山东省药学科学院 一种含有地西泮的鼻腔喷雾剂
EP4458414A3 (en) 2020-12-04 2025-01-01 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
CN118765194A (zh) 2021-12-28 2024-10-11 阿尔库缇斯生物疗法股份有限公司 局部罗氟司特气溶胶泡沫
EP4586999A1 (en) 2022-09-15 2025-07-23 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009139589A2 (en) * 2008-05-14 2009-11-19 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998017315A2 (en) * 1996-10-24 1998-04-30 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
MXPA02001612A (es) * 1999-07-26 2003-10-14 Sk Corp Composiciones anti-convulsivas transnasales y procedimiento modular.
EP1539285B2 (en) * 2002-09-03 2011-10-12 Pharmacure Health Care AB Nasal sprays
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
US7745430B2 (en) * 2006-11-15 2010-06-29 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition
NZ583265A (en) * 2007-08-31 2012-01-12 Archimedes Dev Ltd Pharmaceutical compositions comprising a benzodiazepine drug and a non-aqueous vehicle comprising propylene glycol and propylene carbonate
WO2011034920A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating seizure disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009139589A2 (en) * 2008-05-14 2009-11-19 Sk Holdings Co., Ltd. Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ahmad, Shafique, et al. "Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial." The Lancet 367.9522 (2006): 1591-1597. *
McMullan, Jason, et al. "Midazolam Versus Diazepam for the Treatment of Status Epilepticus in Children and Young Adults: A Meta‐analysis." Academic emergency medicine 17.6 (2010): 575-582. *

Also Published As

Publication number Publication date
MX2013011336A (es) 2013-12-16
SG10201602176RA (en) 2016-04-28
US20120252793A1 (en) 2012-10-04
RU2018135967A (ru) 2018-11-14
CA2831308A1 (en) 2012-10-04
EP2691100A2 (en) 2014-02-05
WO2012135619A2 (en) 2012-10-04
SG193958A1 (en) 2013-11-29
AU2012236334B2 (en) 2017-02-16
BR112013024968A2 (pt) 2016-12-20
PH12017501688A1 (en) 2018-09-10
EP2691100A4 (en) 2014-09-24
MX357800B (es) 2018-07-25
TW201302204A (zh) 2013-01-16
CN103619338B (zh) 2016-06-22
WO2012135619A3 (en) 2012-11-22
AU2012236334A1 (en) 2013-10-10
KR20140029426A (ko) 2014-03-10
AR085927A1 (es) 2013-11-06
HK1195252A1 (zh) 2014-11-07
CN103619338A (zh) 2014-03-05
JP2014509655A (ja) 2014-04-21
RU2013148120A (ru) 2015-05-10
US20140128381A1 (en) 2014-05-08
US20170151258A1 (en) 2017-06-01
PH12013501915A1 (en) 2019-11-29

Similar Documents

Publication Publication Date Title
TWI601532B (zh) 鼻內苯二氮平醫藥組成物
JP2025037885A (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
AU2007290589B2 (en) Pharmaceutical compositions of clonazepam and methods of use thereof
US20260027128A1 (en) Orally inhaled and nasal benzodiazepines
US20160199296A1 (en) Nasal formulations of benzodiazepine
PT2442821T (pt) Administração segura de desmopressina
US20240342407A1 (en) Intranasal desmopressin administration
JP2022514340A (ja) 過剰摂取および報酬に基づく障害を処置するための、組成物、装置、および方法
Karra et al. A review on challenges in developing nasal sprays
HK1195252B (en) Intranasal benzodiazepine pharmaceutical compositions
Sirimanne et al. A Randomized Phase 1 Safety Study of Repeated Doses of Intranasal OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adults: A Potential Treatment for Otitis Media
CN121969353A (zh) 一种溶液型喹硫平经鼻给药的组合物及其应用
AU2017276227A1 (en) Intranasal desmopressin administration

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees